A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Daiichi Sankyo
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
BeOne Medicines
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Astellas Pharma Inc
Incyte Corporation
First Affiliated Hospital of Wenzhou Medical University
G1 Therapeutics, Inc.
AbbVie
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center
Memorial Sloan Kettering Cancer Center
Vasgene Therapeutics, Inc
Hoosier Cancer Research Network
Hoffmann-La Roche
Hoosier Cancer Research Network
Mabwell (Shanghai) Bioscience Co., Ltd.
Altor BioScience
RemeGen Co., Ltd.
SCRI Development Innovations, LLC
National Cancer Institute (NCI)
Hoosier Cancer Research Network
Northwestern University
Tongji Hospital
Hoosier Cancer Research Network
University Health Network, Toronto
Tianjin Medical University Second Hospital
Chinese PLA General Hospital
CG Oncology, Inc.
Shanghai Junshi Bioscience Co., Ltd.
Karolinska University Hospital
H. Lee Moffitt Cancer Center and Research Institute
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Memorial Sloan Kettering Cancer Center
Pierre Fabre Medicament
Bristol-Myers Squibb
Lahey Clinic
Eli Lilly and Company
National Taiwan University Hospital
Association of Urologic Oncology (AUO)